JARDIANCE® Post Marketing Surveillance in Korean Patients With Chronic Kidney Disease (CKD)
The primary objective is to monitor the safety profile of JARDIANCE® in Korean patient with chronic kidney disease (CKD) in routine clinical practice.

The secondary objective is to monitor the efficacy of JARDIANCE® by evaluating changes in urine albumin-creatinine ratio (UACR) after 12 and/or 24 weeks of treatment.
- EligibilityCriteria: Inclusion Criteria:  Age ≧19 years at enrolment Patients diagnosed with CKD Patients with CKD starting JARDIANCE® for the first time in accordance with the approved label in Korea Patients who have provided informed consent and signed the data release consent form  Exclusion Criteria:  Patients with previous exposure to JARDIANCE® Patients with hypersensitivity to empagliflozin or to any of the excipients Patients with type 1 diabetes Patients with history of Diabetic Ketoacidosis (DKA) Patients on dialysis Patients with rare hereditary conditions of galactose intolerance, the Lapp lactase deficiency or glucose-galactose malabsorption Patients who are pregnant or are breastfeeding or who plan to become pregnant during the study period - HealthyVolunteers: No - Gender: All - MinimumAge: 19 Years - StdAgeList: Adult, Older Adult - StudyPopulation: This is a single-arm, open-label, multi-centre observational and non-interventional study (ONIS) based on newly collected data. This study will be carried out by enrolling patients in a consecutive manner into the study requiring completion of case report forms (CRFs) for all participants who initially administered JARDIANCE® following the study start date until the planned number of participants is reached. - SamplingMethod: Probability Sample